hydroxychloroquine has been researched along with Auricular Fibrillation in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the association between hydroxychloroquine (HCQ) initiation and risk of arrhythmia among patients with incident rheumatoid arthritis (RA) or with incident systemic lupus erythematosus (SLE)." | 8.31 | Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study. ( Aviña-Zubieta, JA; Daftarian, N; Esdaile, JM; Hoque, MR; Lu, L; Xie, H, 2023) |
| "To study the relationship between hydroxychloroquine (HCQ) use and new-onset atrial fibrillation in patients with systemic lupus erythematosus (SLE)." | 8.02 | Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus. ( Gupta, A; Manzi, S; Sharma, TS; Shields, KJ; Wasko, MC, 2021) |
| "We assessed the association between hydroxychloroquine (HCQ) initiation and risk of arrhythmia among patients with incident rheumatoid arthritis (RA) or with incident systemic lupus erythematosus (SLE)." | 4.31 | Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study. ( Aviña-Zubieta, JA; Daftarian, N; Esdaile, JM; Hoque, MR; Lu, L; Xie, H, 2023) |
| "To study the relationship between hydroxychloroquine (HCQ) use and new-onset atrial fibrillation in patients with systemic lupus erythematosus (SLE)." | 4.02 | Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus. ( Gupta, A; Manzi, S; Sharma, TS; Shields, KJ; Wasko, MC, 2021) |
| "The incidence and nature of arrhythmias in the setting of COVID-19 were poorly documented across studies." | 2.72 | Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. ( Amarasekera, AT; Kayes, T; Kodsi, M; MacIntyre, CR; Malaty, M; Tan, TC, 2021) |
| "Hydroxychloroquine (HCQ) has been promoted as a potential treatment of coronavirus disease 2019 (COVID-19), but there are safety concerns." | 1.56 | Effects of hydroxychloroquine treatment on QT interval. ( Adabag, S; Bart, B; Hooks, M; Vardeny, O; Westanmo, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoque, MR | 1 |
| Lu, L | 1 |
| Daftarian, N | 1 |
| Esdaile, JM | 1 |
| Xie, H | 1 |
| Aviña-Zubieta, JA | 1 |
| Song, E | 1 |
| Hooks, M | 1 |
| Bart, B | 1 |
| Vardeny, O | 1 |
| Westanmo, A | 1 |
| Adabag, S | 1 |
| Malaty, M | 1 |
| Kayes, T | 1 |
| Amarasekera, AT | 1 |
| Kodsi, M | 1 |
| MacIntyre, CR | 1 |
| Tan, TC | 1 |
| Gupta, A | 1 |
| Shields, KJ | 1 |
| Manzi, S | 1 |
| Wasko, MC | 1 |
| Sharma, TS | 1 |
| Alkasir, A | 1 |
| Lippmann, S | 1 |
1 review available for hydroxychloroquine and Auricular Fibrillation
| Article | Year |
|---|---|
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Atrial Fibrillat | 2021 |
5 other studies available for hydroxychloroquine and Auricular Fibrillation
| Article | Year |
|---|---|
Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atrial Fibrillation; British Columbia; Humans; Hydroxyc | 2023 |
Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium; Electrophysiology; Heart Atria; Humans; Hydrox | 2023 |
Effects of hydroxychloroquine treatment on QT interval.
Topics: Antirheumatic Agents; Atrial Fibrillation; Betacoronavirus; Coronavirus Infections; COVID-19; Drug M | 2020 |
Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus.
Topics: Adult; Aged; Antirheumatic Agents; Atrial Fibrillation; Female; Humans; Hydroxychloroquine; Incidenc | 2021 |
COVID-19 and Cardiac Concerns for Psychiatric Patients.
Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular | 2020 |